Atlas Trials

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Clinical trial NCT03400176 · TERMINATED

Trial details

NCT number
NCT03400176
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia (CLL)
Start date
2018-04-09
Primary completion
2023-09-29
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.